Leptin receptor deficiency confers resistance to behavioral effects of fluoxetine and desipramine via separable substrates

Translational Psychiatry

Volumn 4, Issue 12, 2014, Pages

  Guo, M ^a,b   Lu, X Y ^a,b  

^a BINZHOU MEDICAL UNIVERSITY HOSPITAL   (China)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESIPRAMINE; FLUOXETINE; GLYCOGEN SYNTHASE KINASE 3BETA; LEPTIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; THREONINE; ADRENERGIC RECEPTOR AFFECTING AGENT; LEPTIN RECEPTOR, MOUSE; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; BEHAVIOR; BRAIN CELL; CONTROLLED STUDY; DEPRESSION; FORCED SWIM TEST; GENOTYPE; HIPPOCAMPUS; HYPOTHALAMUS; IMMOBILITY; INTRACELLULAR SIGNALING; LEPTIN DEFICIENCY; LOCOMOTION; LONG TERM CARE; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TAIL SUSPENSION TEST; WILD TYPE; ANIMAL; ANIMAL BEHAVIOR; DEFICIENCY; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG EFFECTS; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; BEHAVIOR, ANIMAL; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DESIPRAMINE; FLUOXETINE; HIPPOCAMPUS; HYPOTHALAMUS; MICE; MICE, KNOCKOUT; PREFRONTAL CORTEX; RECEPTORS, LEPTIN; SEROTONIN UPTAKE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84927783747     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2014.126     Document Type: Article

References (41)

1. Petersen T, Dording C, Neault NB, Kornbluh R, Alpert JE, Nierenberg AA et al. A survey of prescribing practices in the treatment of depression. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 177-187.
2. Whooley MA, Simon GE. Managing depression in medical outpatients. N Engl J Med 2000; 343: 1942-1950.
3. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR, D: implications for clinical practice. Am J Psychiatry 2006; 163: 28-40.
4. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432.
5. Lu XY, Kim CS, Frazer A, Zhang W. Leptin: a potential novel antidepressant. Proc Natl Acad Sci USA 2006; 103: 1593-1598.
6. Garza JC, Guo M, Zhang W, Lu XY. Leptin restores adult hippocampal neurogenesis in a chronic unpredictable stress model of depression and reverses glucocorticoid-induced inhibition of GSK-3beta/beta-catenin signaling. Mol Psychiatry 2012; 17: 790-808.
7. Liu J, Garza JC, Bronner J, Kim CS, Zhang W, Lu XY. Acute administration of leptin produces anxiolytic-like effects: a comparison with fluoxetine. Psychopharmacology (Berl) 2010; 207: 535-545.
8. Yamada N, Katsuura G, Ochi Y, Ebihara K, Kusakabe T, Hosoda K et al. Impaired CNS leptin action is implicated in depression associated with obesity. Endocrinology 2011; 152: 2634-2643.
9. Guo M, Huang TY, Garza JC, Chua SC, Lu XY. Selective deletion of leptin receptors in adult hippocampus induces depression-related behaviours. Int J Neuropsychopharmacol 2013; 16: 857-867.
10. Guo M, Lu Y, Garza JC, Li Y, Chua SC, Zhang W et al. Forebrain glutamatergic neurons mediate leptin action on depression-like behaviors and synaptic depression. Transl Psychiatry 2012; 2: e83.
11. Lawson EA, Miller KK, Blum JI, Meenaghan E, Misra M, Eddy KT et al. Leptin levels are associated with decreased depressive symptoms in women across the weight spectrum, independent of body fat. Clin Endocrinol (Oxf) 2012; 76: 520-525.
12. Esel E, Ozsoy S, Tutus A, Sofuoglu S, Kartalci S, Bayram F et al. Effects of antidepressant treatment and of gender on serum leptin levels in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 565-570.
13. Kraus T, Haack M, Schuld A, Hinze-Selch D, Koethe D, Pollmacher T. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry 2002; 35: 220-225.
14. Laimer M, Kramer-Reinstadler K, Rauchenzauner M, Lechner-Schoner T, Strauss R, Engl J et al. Effect of mirtazapine treatment on body composition and metabolism. J Clin Psychiatry 2006; 67: 421-424.
15. Kloiber S, Ripke S, Kohli MA, Reppermund S, Salyakina D, Uher R et al. Resistance to antidepressant treatment is associated with polymorphisms in the leptin gene, decreased leptin mRNA expression, and decreased leptin serum levels. Eur Neuropsychopharmacol 2013; 23: 653-662.
16. Uher R, Perroud N, Ng MY, Hauser J, Henigsberg N, Maier W et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 2010; 167: 555-564.
17. Beaulieu JM, Gainetdinov RR, Caron MG. Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 2009; 49: 327-347.
18. Chen G, Manji HK. The extracellular signal-regulated kinase pathway: an emerging promising target for mood stabilizers. Curr Opin Psychiatry 2006; 19: 313-323.
19. Gould TD, Picchini AM, Einat H, Manji HK. Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr Drug Targets 2006; 7: 1399-1409.
20. Li X, Jope RS. Is glycogen synthase kinase-3 a central modulator in mood regulationNeuropsychopharmacology 2010; 35: 2143-2154.
21. Wang XZ, Zhang D, Lu XY. Dentate gyrus-CA3 glutamate release/NMDA transmission mediates behavioral despair and antidepressant-like responses to leptin. Mol Psychiatry advance online publication, 5 August 2014; doi: 10.1038/mp.2014.75 (e-pub ahead of print).
22. Katz MM, Koslow SH, Maas JW, Frazer A, Bowden CL, Casper R et al. The timing, specificity and clinical prediction of tricyclic drug effects in depression. Psychol Med 1987; 17: 297-309.
23. Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 2001; 62: 869-877.
24. Thase ME, Haight BR, Richard N, Rockett CB, Mitton M, Modell JG et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005; 66: 974-981.
25. Scott MM, Lachey JL, Sternson SM, Lee CE, Elias CF, Friedman JM et al. Leptin targets in the mouse brain. J Comp Neurol 2009; 514: 518-532.
26. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-770.
27. Leshan RL, Bjornholm M, Munzberg H, Myers MG Jr. Leptin receptor signaling and action in the central nervous system. Obesity (Silver Spring) 2006; 14: 208S-212S.
28. Nelson JC. Managing treatment-resistant major depression. J Clin Psychiatry 2003; 64: 5-12.
29. Preskorn SH. Antidepressant drug selection: criteria and options. J Clin Psychiatry 1994; 55: 6-22, discussion 23-24, 98-100.
30. Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010; 67: 220-229.
31. Kivimaki M, Lawlor DA, Singh-Manoux A, Batty GD, Ferrie JE, Shipley MJ et al. Common mental disorder and obesity: insight from four repeat measures over 19 years: prospective Whitehall II cohort study. BMJ 2009; 339: b3765.
32. Markowitz S, Friedman MA, Arent SM. Understanding the relation between obesity and depression: causal mechanisms and implications for treatment. Clin Psychol Sci Pract 2008; 15: 1-20.
33. Sharma AN, Elased KM, Garrett TL, Lucot JB. Neurobehavioral deficits in db/db diabetic mice. Physiol Behav 2010; 101: 381-388.
34. Grzanna R, Molliver ME. The locus coeruleus in the rat: an immunohistochemical delineation. Neuroscience 1980; 5: 21-40.
35. Swanson LW. The locus coeruleus: a cytoarchitectonic, Golgi and immunohistochemical study in the albino rat. Brain Res 1976; 110: 39-56.
36. Elmquist JK, Bjorbaek C, Ahima RS, Flier JS, Saper CB. Distributions of leptin receptor mRNA isoforms in the rat brain. J Comp Neurol 1998; 395: 535-547.
37. Lam DD, Leinninger GM, Louis GW, Garfield AS, Marston OJ, Leshan RL et al. Leptin does not directly affect CNS serotonin neurons to influence appetite. Cell Metab 2011; 13: 584-591.
38. Azmitia EC, Segal M. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J Comp Neurol 1978; 179: 641-667.
39. Berridge CW, Waterhouse BD. The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Brain Res Rev 2003; 42: 33-84.
40. Mason ST, Fibiger HC. Regional topography within noradrenergic locus coeruleus as revealed by retrograde transport of horseradish peroxidase. J Comp Neurol 1979; 187: 703-724.
41. Moore RY, Halaris AE. Hippocampal innervation by serotonin neurons of the midbrain raphe in the rat. J Comp Neurol 1975; 164: 171-183.